ReportsnReports.com adds two brand new market research reports on the In Vitro Diagnostics Industry covering The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 8th Edition as well as US In Vitro Diagnostics to 2016.
This study on In Vitro Diagnostics, priced at $5100, presents historical demand data for 2001, 2006 and 2011, as well as forecasts for 2016 and 2021 by product, application, and market. This study also considers key market environment factors, evaluates company market share, and profiles 27 competitors in the US IVD industry.
IVD demand in US to reach nearly $25 billion in 2016
US demand for in vitro diagnostic (IVD) products will rise more than six percent annually to nearly $25 billion in 2016. Aging demographic patterns, expanding levels of health insurance coverages, and new product introductions will underlie gains. Growth in the middle aged and elderly population segments will boost overall health care needs, leading to a rising volume of IVD tests. The extension of health insurance coverage attributable to the Affordable Health Care Act of 2010 will make basic and specialized IVD procedures available to a greater number of individuals. Advances in cellular analysis, molecular diagnostic and other advanced technologies will expand applications for IVD products in disease detection, forensic medical, and identity testing.
Clinical chemistry, immunoassay to remain top products
Clinical chemistry and immunoassay will remain the top two IVD methodologies, the former based on sales of personal blood glucose monitors and test strips and the latter due to the penetration of high value-added chemiluminescent products into infectious disease and drug testing markets. Molecular diagnostic products will post the fastest growth in demand among all IVD products based on throughput, accuracy, and speed advantages, especially in the detection of infectious diseases and cancer markers. Diabetes testing will remain the largest IVD application through 2016 and beyond due to increasing blood glucose monitoring among afflicted patients.
Hemostasis tests for cardiac conditions offer best growth
Based on their ability to quantify heart attack and embolism risk prior to occurrence, hemostasis tests for D-dimer and other cardiac parameters will command the best growth among IVD blood testing products. Demand for molecular diagnostic products will expand at a strong pace as next-generation PCR (polymerase chain reaction) and FISH (fluorescence in situ hybridization) penetrate applications involving the analysis, characterization, and therapeutic monitoring of complex infections and tumors. DNA-based forensic, genetic, and identity testing will comprise one of the fastest growing IVD applications through 2016 as the vast potential of law enforcement and genetic screening markets begins to translate into significant revenues. Among other IVD products, cellular analysis and anatomical pathology reagents and instruments will post the best sales gains. Cellular analysis techniques will continue to dominate cervical cancer testing and penetrate additional cancer diagnostic applications. Anatomical pathology will remain the leading IVD technique for biopsy-based cancer and infectious disease detection.
Diabetes testing to benefit clinical chemistry reagents & instruments
Evolving epidemiological trends and patient care approaches will impact favorably on growth opportunities for most types of IVD products. The market for clinical chemistry reagents and instruments will benefit from an increasing number of diabetic patients engaging in self-blood glucose monitoring and the expanding use of general health screening in routine patient examinations. The widening availability of chemiluminescent tests with inherent sensitivity and selectivity advantages will broaden applications for immunoassays in therapeutic drug monitoring, drugs of abuse detection, and infectious disease testing.
Explore Table of Contents, Request A Sample for purchase consideration or Buy your copy of this report @: http://www.reportsnreports.com/reports/183965-in-vitro-diagnostics-to-2016.html
This edition features a demonstrative increase of hundreds of pages from the 2010 edition as new companies have entered the diagnostic market and IT companies make their mark on diagnostics.
Comprehensive Coverage of a High Interest Industry
The report is over 1400 pages, reflecting the dramatic change in IVD. New entrants, net technologies have entered the stage and all important events are cataloged in this report. The idea behind this unique report is that the entire market can be captured in one volume and business planners avoid multiple purchases. Published every two years, this volume includes coverage of the most important aspects of all of the major segments of clinical lab testing, including:
Comprehensive Coverage of a High Interest Industry
The report is over 1400 pages, reflecting the dramatic change in IVD. New entrants, net technologies have entered the stage and all important events are cataloged in this report. The idea behind this unique report is that the entire market can be captured in one volume and business planners avoid multiple purchases. Published every two years, this volume includes coverage of the most important aspects of all of the major segments of clinical lab testing, including:
- Point of Care (POC), (Professional and Self-Testing)
- Histology and Cytology (Pap, ISH, IHC, traditional non-pap, HPV)
- Core Lab (General Chemistries, Workstations, Analyzers)
- Immunoassays (Blood Gases, Urinalysis, Critical Care)
- Molecular Assays (Infectious Disease, Blood Screening, Inherited Diseases, Oncology, Pharmacodiagnostics, Tissue Typing, Prenatal)
- Hematology
- Coagulation (Lab-Based, POC, Genetic Markers)
- Microbiology and Virology
- Blood Banking (Grouping, Immunoassay Screens, NAT Screens)
Market sizes, forecasts and shares are provided, as well as a geographic breakdown of the segments, where possible. Changes in technology development, regulatory and reimbursement issues, clinical care, and business environments are discussed. Current market numbers are presented for 2011, with projections given through 2016.
The "Bible of the IVD Industry"
Now in 8 editions, this report has become the go-to market research reference for the industry. Many of the top IVD companies use this product for business planning, which means that this volume can provide a uniform standard for in vitro diagnostic market numbers. This edition greatly expands coverage of the field and tracks the most important developments. See aspects of the industry that might not be available in your company's internal resources. View the market from an independent point of view. Learn about competitors in away that may be invisible to internal personnel. Know the market players - your competitors and potential partners, in proper context and classification. Save countless hours of staff time and other research expenses with the authoritative guide for IVD market estimates and forecasts.
A Global Report
From the first edition, this report was designed as a global resource in order to give market-watchers a true picture of the industry. IVD is a worldwide business. While the US is a large healthcare market, much of the dynamism, the growth, and also competition is occurring in other areas. Many of the most interesting opportunities for companies are occurring in emerging markets. As part of its coverage, the report breaks down the entire IVD market for the following regions: North America, Europe (EU countries, incl. IVD market sizes by country), Eastern Europe, South America, Asia (Japan, China and India) and Rest of World.
The "Bible of the IVD Industry"
Now in 8 editions, this report has become the go-to market research reference for the industry. Many of the top IVD companies use this product for business planning, which means that this volume can provide a uniform standard for in vitro diagnostic market numbers. This edition greatly expands coverage of the field and tracks the most important developments. See aspects of the industry that might not be available in your company's internal resources. View the market from an independent point of view. Learn about competitors in away that may be invisible to internal personnel. Know the market players - your competitors and potential partners, in proper context and classification. Save countless hours of staff time and other research expenses with the authoritative guide for IVD market estimates and forecasts.
A Global Report
From the first edition, this report was designed as a global resource in order to give market-watchers a true picture of the industry. IVD is a worldwide business. While the US is a large healthcare market, much of the dynamism, the growth, and also competition is occurring in other areas. Many of the most interesting opportunities for companies are occurring in emerging markets. As part of its coverage, the report breaks down the entire IVD market for the following regions: North America, Europe (EU countries, incl. IVD market sizes by country), Eastern Europe, South America, Asia (Japan, China and India) and Rest of World.
A Report Designed for a Changing Industry
A number of totally disparate phenomena have come together to change the IVD industry. Human genome research is finding links between a person’s genome and several lifestyle situations such as nutrition, dieting, skin conditions and other essentially non-medical conditions. This has attracted consumer product companies such as Proctor & Gamble and Nestlé to develop products and services based on IVD technologies. Decreases in life science grants have encouraged companies active in this space to migrate their technologies for clinical applications.
The result is the entry of companies such as Caliper Life Sciences, Illumina, Affymetrix and Life Technologies to the diagnostics market with products and test services. Miniaturization of traditional immunoassay and molecular test technologies has finally matured to the point where they may be ready for scale-up and then commercialization into products. Here electronics companies such as Sony, Samsung, Dell Computers and Intel Corp. have invested in clinical diagnostics ventures. These exciting developments join expansion into new market segments by companies already involved in the IVD industry.
In 2010 and 2011, there were at least 74 acquisitions and some 36 distribution agreements. And this is only a small portion of what is really happening. There are many more deals that have not been announced. The goal is to build better tests and stronger companies. The future of the industry lies in the development of more sensitive, faster, user-friendly, IT capable devices for a host of new protein and molecular markers.
In this eighth edition of The Worldwide Market for In Vitro Diagnostic Tests Kalorama Information addresses all of the key issues affecting the diagnostic industry in 2012 and how competitors are faring. Among the topics tackled in this report:
Molecular diagnostics including infectious disease mdx, pharmacodiagnostics, molecular poc and test services are put in a context.
The result is the entry of companies such as Caliper Life Sciences, Illumina, Affymetrix and Life Technologies to the diagnostics market with products and test services. Miniaturization of traditional immunoassay and molecular test technologies has finally matured to the point where they may be ready for scale-up and then commercialization into products. Here electronics companies such as Sony, Samsung, Dell Computers and Intel Corp. have invested in clinical diagnostics ventures. These exciting developments join expansion into new market segments by companies already involved in the IVD industry.
In 2010 and 2011, there were at least 74 acquisitions and some 36 distribution agreements. And this is only a small portion of what is really happening. There are many more deals that have not been announced. The goal is to build better tests and stronger companies. The future of the industry lies in the development of more sensitive, faster, user-friendly, IT capable devices for a host of new protein and molecular markers.
In this eighth edition of The Worldwide Market for In Vitro Diagnostic Tests Kalorama Information addresses all of the key issues affecting the diagnostic industry in 2012 and how competitors are faring. Among the topics tackled in this report:
Molecular diagnostics including infectious disease mdx, pharmacodiagnostics, molecular poc and test services are put in a context.
- Merging IT and IVD: Establishing the EMR Record from IVD Tests
- Healthcare Reform and its Possible Impact on IVD.
- The Status of Automation in the Lab; Core Lab Section Includes Both Workstation and Automated Panel Revenues.
- Mass Spec, Next Gen Sequencing and Other Technology Entrants
- Hospital Infection Testing - the latest
- Several Hundred Company profiles. Top tier companies, Second and Third Tier companies but also Smaller Innovators. The report‘s profiles distinguish between companies that are leaders in all aspects of IVD, those that are Specialists in one particular area or a few.
- Major Mergers as well as Partnerships, Distribution Agreements.
- Brazil, India and China - Important Emerging Markets for IVD.
- Innovations in Blood Banking
- Histology/Cytology innovations; the role of FISH testing and Digital Images
- Healthcare statistics for various countries -healthcare spending as a percent of GDP, new hospitals, cost increases and other information.
- Tables that document the most competitive products on the market and under development in each area of IVD.
- Country-level Breakout of IVD market for major European and Asian countries.
- The Current Economic Situation
- Update on the Regulation of Novel Devices
Explore Table of Contents, Request A Sample for purchase consideration or Buy your copy of this report @: http://www.reportsnreports.com/reports/183811-the-worldwide-market-for-in-vitro-diagnostic-ivd-tests-8th-edition.html
You may also be interested in other reports on the Biotechnology Market available @ http://www.reportsnreports.com/market-research/biotechnology/
Contact sales@reportsandreports.com for further information or for your specific requirements.
No comments:
Post a Comment